Gonadotrophin-releasing hormone antagonists for assisted conception

Background Gonadotrophin-releasing hormone antagonists produce immediate suppression of gonadotrophin secretion, hence, they can be given after starting gonadotrophin administration. This has resulted in dramatic reduction in the duration of treatment cycle. Two different regimes have been described. The multiple-dose protocol involves the administration of 0.25 mg cetrorelix ( or ganirelix) daily from day six to seven of stimulation, or when the leading follicle is 14 to 15 mm, until human chorionic gonadotrophin ( HCG) administration and the single-dose protocol involves the single administration of 3 mg cetrorelix on day seven to eight of stimulation. Assuming comparable clinical outcome, these benefits would justify a change from the standard long protocol of GnRH agonists to the new GnRH antagonist regimens. Objectives To evaluate the evidence regarding the efficacy of gonadotrophin-releasing hormone ( GnRH) antagonists with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception. Search strategy We searched Cochrane Menstrual Disorders and Subfertility Group's Specialised Register, MEDLINE and EMBASE databases from 1987 to February 2006, and handsearched bibliographies of relevant publications and reviews, and abstracts of scientific meetings. We also contacted manufacturers in the field. Selection criteria Randomized controlled studies comparing different protocols of GnRH antagonists with GnRH agonists in assisted conception cycles were included in this review. Data collection and analysis Two authors independently assessed trial quality and extracted data. If relevant data were missing or unclear, the authors have been consulted Main results Twenty seven RCTs comparing the GnRH antagonist to the long protocol of GnRH agonist fulfilled the inclusion criteria. Clinical pregnancy rate was significantly lower in the antagonist group. ( OR = 0.84, 95% CI = 0.72 - 0.97). The ongoing pregnancy/live-birth rate showed the same significant lower pregnancy in the antagonist group ( P = 0.03; OR 0.82, 95% CI 0.69 to 0.98). However, there was statistically significant reduction in incidence of severe OHSS with antagonist protocol. The relative risk ratio was ( P = 0.01; RR 0.61, 95% CI 0.42 to 0.89). In addition, interventions to prevent OHSS ( e. g. coasting, cycle cancellation) were administered more frequently in the agonist group ( P = 0.03; OR 0.44, 95% CI 0.21 to 0.93). Authors' conclusions GnRH antagonist protocol is a short and simple protocol with good clinical outcome with significant reduction in incidence of severe ovarian hyperstimulation syndrome and amount of gonadotrophins but the lower pregnancy rate compared to the GnRH agonist long protocol necessitates counseling subfertile couples before recommending change from GnRH agonist to antagonist.